Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Omada HealthFRA:U76 -4.33%13 EV-to-EBITDA is 119.25 as of Aug. 18, 2026. GuruFocus rates FRA:U76 with a GF Score™ of 13/100. The stock has 4 warning signs investors should review. Among 511 Healthcare Providers & Services companies, Omada Health ranks worse than 95.89% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Omada Health's enterprise value is €1,089.3 Mil.
Omada Health's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was €9.1 Mil. Therefore, Omada Health's EV-to-EBITDA for today is 119.25.
The historical rank and industry rank for Omada Health's EV-to-EBITDA or its related term are showing as below:
FRA:U76'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -156.37 Med: -14.02 Max: 1207.51
Current: 118.96
During the past 4 years, the highest EV-to-EBITDA of Omada Health was 1207.51. The lowest was -156.37. And the median was -14.02.
FRA:U76's EV-to-EBITDA is ranked worse than 95.89% of 511
companies
in the Healthcare Providers & Services industry
Industry Median: 10.66
vs FRA:U76: 118.96
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Omada Health's PE Ratio (TTM) for today is calculated as:
Omada Health's share price for today is €19.90.
Omada Health's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.043.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Omada Health's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:U76 vs CERT, SDGR, GDRX: EV-to-EBITDA Comparison
For the Health Information Services subindustry, Omada Health's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Omada Health EV-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Omada Health's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Omada Health's EV-to-EBITDA falls into.
Omada Health's current Enterprise Value is €1,089.3 Mil.
Omada Health's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €9.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Omada Health (FRA:U76) has a EV-to-EBITDA of 119.25 as of Aug. 18, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Omada Health. According to the industry distribution chart, Omada Health ranks #490 out of 511 companies in the Healthcare Providers & Services industry, placing it in the top 95.9%.
Is Omada Health's EV-to-EBITDA too high?
Omada Health's current EV-to-EBITDA is 119.25. The Healthcare Providers & Services industry median EV-to-EBITDA is 10.66. Omada Health's value of 119.25 is 1018.7% above this industry median. Based on the distribution chart, Omada Health ranks #490 out of 511 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Omada Health has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Omada Health's EV-to-EBITDA compare to CERT and SDGR?
According to the Healthcare Providers & Services industry distribution chart, Omada Health ranks #490 out of 511 companies for EV-to-EBITDA. This places Omada Health in the lower half of its industry. The industry median EV-to-EBITDA is 10.66. Omada Health's value of 119.25 is 1018.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Healthcare Providers & Services company?
The median EV-to-EBITDA among Healthcare Providers & Services companies is 10.66, based on 511 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Omada Health's current EV-to-EBITDA of 119.25 is 1018.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Omada Health. For the Healthcare Providers & Services industry, the median EV-to-EBITDA is 10.66 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Omada Health's current EV-to-EBITDA is 119.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Omada Health stock overvalued right now?
Omada Health (FRA:U76) has a current EV-to-EBITDA of 119.25. The current EV-to-EBITDA is 119.25 and 1018.7% above the Healthcare Providers & Services industry median of 10.66. Omada Health's overall GF Score™ is 13/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Omada Health (FRA:U76), the current EV-to-EBITDA is 119.25 as of Aug. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Omada Health Inc empowers individuals to make lasting health changes through personalized, virtual care between doctor's visits. The integrated platform of the company supports members with cardiometabolic conditions like prediabetes, diabetes, hypertension, musculoskeletal issues, and behavioral health needs. The company's specialized care tracks also assist members using GLP-1 medications. The company delivers measurable health outcomes and value for employers, health plans, health systems, and pharmacy benefit managers.
13GF Score
Get the complete analysis for FRA:U76
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:U76 has been successfully added to your 
